HeyJaredPerspectives by the Leerink Center for Pharmacoeconomics
Welcome to Perspectives, a signature podcast series from the Leerink Center for Pharmacoeconomics. Hosted by Dr.
- Indexed episodes, last 90 days
- 3
- Latest publication
- Aug 31, 2026
- Audience
- Checking…
- Earliest in this view
- Jul 8, 2026
Latest episodes
How Do WAC, AMP, ASP, 340B, and MFP Fit Together? A Branded Drug Pricing 101 with Inma Hernandez (opens the original)
Read excerpt
Inma Hernandez, PharmD, PhD, Senior Advisor for Drug Prices at the Centers for Medicare and Medicaid Services, joins Perspectives to give an overview of drug pricing regulatory dynamics for branded drugs in the US. The episode is a step-by-step walkthrough of the different prices a branded drug can have in the U.S. and how those prices are established across commercial insurance, Medicaid, Medicare Part B, and Medicare Part D. Inma explains the alphabet soup of WAC, AMP, best price, ASP, and MFP
Can Health Economics Lead to Better Biotech? A Conversation with Rob Abbott (opens the original)
Read excerpt
Rob Abbott, CEO of ISPOR, joins Perspectives to talk about why health economics and outcomes research (HEOR) has become more relevant for biotech founders, executives, and investors. The conversation challenges the common perception that HEOR is primarily a post-approval exercise used to support pricing and reimbursement. Instead, Rob discusses how evidence generation, economic modeling, and value strategy can shape clinical development, inform investment decisions, and strengthen the commercial
What Happens When Drug Pricing Meets Trade Policy? A Conversation with Ron Lanton (opens the original)
Read excerpt
Ron Lanton, the Founder and President of Lanton Strategies International, joins Perspectives by the Leerink Center for Pharmacoeconomics to discuss the use of trade mechanisms to address pharmaceutical pricing. Ron provides insight into the growing intersection of pharmaceutical pricing and international trade policy, why recent developments could be significant, and what it could mean for biopharmaceutical companies, investors, and patients. Topics discussed include: U.S. Trade Representative’s
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.
See coverage about Perspectives by the Leerink Center for Pharmacoeconomics